CRO directory 2026

    Clinical Research Organizations in Jordan

    Jordan is the Levant’s clinical-research workshop: Amman CROs and bioequivalence units can file a JFDA protocol in English, King Hussein Cancer Center and the university hospitals can enrol Arabic-speaking patients at Gulf-adjacent quality, and a generation of monitors already knows FDA and EMA language from US-bound generic files.

    IQVIA’s Amman desk delivers the country inside global Phase II–III programmes. ClinServ and other regional houses use Jordan as a Levant hub when a protocol also needs Palestine, Iraq or Gulf overflow. Triumpharma and the Pharmaceutical Research Unit dominate much of the bioequivalence and healthy-volunteer work that Jordanian and regional generic manufacturers need for JFDA and GCC files. King Hussein Cancer Center is the oncology site sponsors name without being prompted. Jordan University Hospital, King Abdullah University Hospital at JUST in Irbid, and the larger private hospitals — Istishari, Specialty, Abdali — add beds and investigators. The Jordan Food and Drug Administration authorises interventional studies and inspects BE units; hospital IRBs are the second clock. This directory separates global monitors, Jordanian BE houses, regional CROs, academic and cancer sites and the Authority so a sponsor can match the vendor to the study type rather than briefing “Amman research” as one shop.

    Updated September 2026 · Jordan Food and Drug Administration (JFDA) — clinical trials authorisation and inspected bioequivalence units as of September 2026 · 16 named accounts

    Request a proposal for JordanBrowse the 16 companies

    1

    National authority that authorises drug trials and inspects BE units (JFDA)

    KHCC

    King Hussein Cancer Center — the oncology site most industry feasibility notes already name

    2

    Study types that dominate local CRO revenue: bioequivalence for generics, and late-phase / oncology for industry

    Amman + Irbid

    Cities that recur on industry site lists (university hospitals plus KHCC and private tertiary)

    Named accounts

    Top clinical research organizations (CROs) in Jordan

    Public, well-known names BioNixus studies at account and SKU level. This is an editorial snapshot, not an endorsement or a market-share ranking. Cross-checked against Jordan Food and Drug Administration (JFDA) — clinical trials authorisation and inspected bioequivalence units (as of 2026-09-05).
    #CompanyHQ
    01IQVIA JordanAmman
    02ClinServAmman
    03TriumpharmaAmman
    04Pharmaceutical Research Unit (PRU)Amman
    05Pharmaceutical Solutions CenterAmman
    06King Hussein Cancer Center (KHCC)Amman
    07Jordan University HospitalAmman
    08King Abdullah University Hospital (JUST)Irbid
    09Istishari HospitalAmman
    10Specialty HospitalAmman
    11Abdali HospitalAmman
    12ICON / Fortrea / Syneos — Jordan country coverageAmman
    13Jordan Food and Drug Administration (JFDA) — clinical trialsAmman
    14Ministry of Health — hospital research governanceAmman
    15University of Jordan — Institutional Review BoardAmman
    16Royal Medical Services — research officeAmman

    Primary research

    These are the clinical research partners we benchmark in Jordan

    Selecting sites or a CRO in Jordan? BioNixus runs investigator and site-feasibility interviews, patient-pathway mapping and competitor-trial landscaping. Proposal within 48 hours.

    Planning research in Jordan?

    Primary research, market access & HEOR. Proposals within 48 hours.

    Top market research companies in Jordan (2026)

    How the market is structured

    How JFDA, Amman BE units and KHCC sites run a Jordanian study

    Pick the study type first. A bioequivalence file for a Jordanian, Iraqi or GCC generic usually goes to Triumpharma or the Pharmaceutical Research Unit — EDA- and JFDA-familiar clinical pharmacology units with a GCP ward and a bioanalytical lab that already ship chromatograms to Gulf regulators. A multinational Phase III goes to IQVIA or another global CRO, which then contracts King Hussein Cancer Center, Jordan University Hospital, King Abdullah University Hospital in Irbid, or a private tertiary such as Istishari. A mid-sized regional protocol often lands on ClinServ or a local monitoring shop that can also cover Levant overflow. Every interventional drug study needs JFDA authorisation and a local IRB letter; a foreign sponsor without a Jordanian entity appoints a legal representative, which is everyday business for the Amman CRO bench. Start-up time is driven by the hospital research office as much as by the Authority — KHCC and the university hospitals are used to industry contracts, district hospitals are not. Samples for global trials still travel to European or Gulf central labs; BE samples stay on the Amman campus. English protocol language is not the barrier here; Arabic patient materials, insurance wording and the JFDA’s clinical-trials unit calendar are. Feasibility that quotes “Jordan as a cheap EU bridge” without naming KHCC versus a BE ward will miss first-patient by months.

    Local

    Amman bioequivalence houses — Triumpharma, PRU, Pharmaceutical Solutions — and the hospital research offices that actually enrol.

    • Triumpharma
    • Pharmaceutical Research Unit (PRU)
    • Pharmaceutical Solutions Center

    Multinational

    IQVIA and other global CROs that run Jordanian sites inside multinational books, often from a lean Amman desk or a visiting CRA model.

    • IQVIA Jordan
    • ICON / Fortrea / Syneos — Jordan country coverage

    Regional

    ClinServ and Levant-hub monitors that treat Jordan as a base for Palestine, Iraq or Gulf overflow rather than as a standalone EU-style country office.

    • ClinServ

    Sites, SMOs & regulators

    JFDA clinical-trials unit, hospital IRBs, Ministry of Health governance and Royal Medical Services — the files and ethics boards that sit above any CRO logo.

    • King Hussein Cancer Center (KHCC)
    • Jordan University Hospital
    • King Abdullah University Hospital (JUST)
    • Istishari Hospital
    • Specialty Hospital
    • Abdali Hospital
    • Jordan Food and Drug Administration (JFDA) — clinical trials
    • Ministry of Health — hospital research governance
    • University of Jordan — Institutional Review Board
    • Royal Medical Services — research office

    What is moving

    What is moving clinical research in Jordan

    Bioequivalence as a regional export service

    Jordanian BE units still file for GCC and Levant generics; that work funds the GCP wards that industry late-phase teams later borrow.

    KHCC as an oncology magnet

    A single cancer centre with industry-ready contracts pulls protocols that would otherwise skip the Levant for Turkey or Egypt.

    English-and-Arabic dual language

    Investigators and CRAs who can run an FDA-style file in English and consent patients in Arabic remain Jordan’s practical advantage over several larger neighbours.

    Levant overflow and Gulf referral

    Sponsors that already use ClinServ or IQVIA in the Gulf add Jordan when they need Arabic enrolment without Egypt’s volume politics or Turkey’s TİTCK calendar.

    BioNixus fieldwork

    How BioNixus studies clinical research organizations (CROs) in Jordan

    The accounts above are the ones our field teams and analysts work with. What a brand team typically commissions from us in Jordan:
    • KHCC and university-hospital research-office interviews on oncology versus multi-specialty start-up clocks.
    • Amman BE-unit walkthroughs at Triumpharma and PRU that separate inspected wards from brochure capacity.
    • JFDA clinical-trials unit timing for industry Phase III versus generic bioequivalence files.
    • Private-tertiary (Istishari, Specialty, Abdali) investigator interviews on insured-specialty enrolment versus university volume.

    Questions

    Frequently Asked Questions

    Who authorises clinical trials in Jordan?

    The Jordan Food and Drug Administration for interventional drug studies, plus a hospital or university IRB. A foreign sponsor without a local entity appoints a legal representative.

    Where should oncology feasibility start?

    King Hussein Cancer Center first, then university hospitals if the protocol needs additional investigators. Private tertiary sites are a third door, not a substitute for KHCC.

    Who runs bioequivalence studies in Jordan?

    Triumpharma and the Pharmaceutical Research Unit are the houses generic manufacturers name. Inspect the clinical ward and the bioanalytical lab; do not treat them as interchangeable with IQVIA.

    Is Jordan only an Amman market for trials?

    Amman holds KHCC, Jordan University Hospital and the private tertiary sites. King Abdullah University Hospital in Irbid is the northern academic door and should be on any national feasibility.

    What fieldwork does BioNixus run on Jordanian CROs and sites?

    Investigator and research-office interviews at KHCC, university hospitals and private tertiary sites; BE-unit capability checks in Amman; and JFDA start-up timing for industry versus generic files.

    Does table order rank Jordanian CROs?

    No. Names appear because they recur in BioNixus Levant feasibility work. The sort is by role: global monitor, BE house, regional CRO, site, authority.

    Sources

    Data sources & methodology

    This directory aggregates publicly available company and channel facts — filings, brand sites, and BioNixus fieldwork in Jordan. It is an editorial snapshot of the accounts we study, not a share ranking and not a substitute for NielsenIQ, IQVIA, or another syndicated feed.

    Primary register: Jordan Food and Drug Administration (JFDA) — clinical trials authorisation and inspected bioequivalence units, consulted 2026-09-05. Company classification (Local / MNC / Regional / sites, smos & regulators) reflects ownership and role in Jordan, not size.

    • JFDA clinical-trials and bioequivalence-unit materials
    • King Hussein Cancer Center and university-hospital research-office public materials
    • Company and service descriptions of IQVIA Jordan, ClinServ, Triumpharma and the Pharmaceutical Research Unit
    • BioNixus Jordan and Levant clinical-research feasibility fieldwork, 2023–2026

    BioNixus sells account-level and SKU-level primary research that complements those subscriptions. For a scoped proposal, contact the team or use the form below. Email admin@bionixus.com.

    48-hour proposal

    Need site and investigator intelligence in Jordan?

    Feasibility, recruitment realism and investigator preference — from the sites, not the sponsor deck.

    Planning research in Jordan?

    Primary research, market access & HEOR. Proposals within 48 hours.